Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2001-11-09
2004-03-16
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S280000, C514S284000, C514S285000
Reexamination Certificate
active
06706704
ABSTRACT:
FIELD OF THE INVENTION
The invention is directed to method of inducing opioid analgesia and anesthesia in mammals, including humans, without suppressing respiration.
BACKGROUND
Opiates have long been known to disrupt respiratory rhythm and to depress breathing and respiratory sensitivity to CO
2
(Jaffe and Martin, 1990). The pons and medulla are known to be the primary sites where opiate drugs produce these respiratory effects (Id.). Endogenous opioids as well as &mgr;- and &dgr;-subtypes of opioid receptors are present in essentially all respiratory regions of the pons and medulla (Yeadon and Kitchen, 1989). In vivo and in vitro investigations have shown that exogenous opioids depress inspiratory and expiratory neuronal activity postsynaptically (Denavit-Saubie', Champagnat and Zieglgansberger, 1978), as well as presynaptically (Johnson, Smith and Feldman, 1996). The underlying cellular mechanisms responsible for the opiate effects on respiration have not, however, been elucidated.
Opiates are widely used medicinal agents. However, because they depress breathing, their use is contraindicated in many instances, especially in patients with compromised cardiovasculare and pulmonary function. Thus, there has been a long-felt need to harness the analgesic power of the opiates, without depressing the respiratory function of the patient.
SUMMARY OF THE INVENTION
In the present invention, actions of opiates were analyzed on bulbospinal inspiratory and expiratory neurons and on non-bulbospinal postinspiratory neurons of the medulla in cats that were either anesthetized with pentobarbital or &agr;-chloralose, or rendered comatose in the unanesthetized state by midcollicular decerebration. The cat respiratory network is similar to that of man. The different cat preparations were used to determine how opiate-induced respiratory responses are affected by anesthetics with different effects on the reticular activating system (RAS; Killlam, 1967). The RAS provides a source of excitatory synaptic input to the brainstem respiratory network (Richter, Ballantyne and Remmers 1986), and is also a site of action for opiates (Killam, E. K. 1963). Most of the respiratory neurons in this study were identified as bulbospinal and therefore might be directly responsible for opiate-mediated depression of tidal volume (Jaffe and Martin, 1990; Shook et al., 1990) and decreased chest wall compliance (Marty and Desmonts, 1981; Bennett, Abrams, Van Riper and Horrow, 1997; Neidhart, Burgener and Suter, 1989).
With respect to this invention, it was also important to ascertain whether anesthesia would compromise the potential of D
1
dopamine agonists to antagonize opioid-mediated respiratory depression. This is an important issue because opioids and anesthetics are frequently used in combination during surgical procedures.
Another objective of this work was to determine if opioid depression of the respiratory network is reversed by administration of selective D
1
-dopamine receptor agonists. Reversal of opioid depression with a D
1
agonist had been previously demonstrated by Lalley and coworkers in an in vitro brainstem-spinal cord preparation of the neonatal rat (Ballanyi, Lalley, Hoch and Richter 1997). This work, however, cannot be extrapolated to in vivo efficacy due to the rudimentary nature of the in vitro spinal cord preparation. Experimentation in a more developmentally mature and intact animal model was required to determine if this type of antagonism is also possible in vivo in the respiratory network of mature mammals. The results discussed herein reveal that D
1
agonists are indeed effective in each of the different cat animal models, and reinstate a normal respiratory rhythm without directly stimulating the network or increasing brain stem or carotid body chemoreceptor sensitivity.
Thus, a first embodiment of the present invention is directed to a pharmaceutical composition for inducing analgesia or anasthesia in a mammalian subject, while simultaneously eliminating or inhibiting respiratory depression in the subject. The pharmaceutical composition comprises, in combination, an opiate or opioid analgesic or anesthetic, a D
1
-dopamine receptor agonist, and a pharmaceutically-suitable carrier therefor. More specifically, in the preferred composition, the opiate or opioid is selected from the group consisting of alfentanil, buprenorphine, carfentanil, codeine, dihydrocodeine, diprenorphine, etorphine, fentanyl, heroin, hydrocodone, hydromorphone, LAAM, levorphanol, meperidine, methadone, morphine, naloxone, naltrexone, beta-hydroxy-3-methylfentanyl, oxycodone, oxymorphone, propoxyphene, remifentanil, sufentanil, tilidine, tramadol, enriched or pure enantiomers or diastereomers thereof; racemic mixtures thereof; and pharmaceutically-suitable salts thereof; and the D
1
-dopamine receptor agonist is selected from the group consisting of (±)-1-phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diol; (−)-(6aR,12bR)-4,6,6a,7,8,12b-hexahydro-7-methylindolo{4,3-a}phenanthridine; (±)-trans-10,11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo-{a}phenanthridine; (±)-6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine; (±)-6-chloro-7, 8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine; ABT 431; enriched or pure enantiomers or diastereomers thereof; racemic mixtures thereof; and pharmaceutically-suitable salts thereof.
A second embodiment of the invention is directed to a method of inhibiting respiratory depression in mammals during treatment with opiates or opioids. The method comprises administering to a mammalian subject being treated with opiates or opioids, an amount of a D
1
-dopamine receptor agonist, the amount being sufficient to inhibit respiratory depression. The preferred D
1
-dopamine receptor agonists for use in the method are the same as those listed in the previous paragraph. Likewise, the method will function with equal success regardless of the specific opiate or opioid that is being used to treat the subject.
REFERENCES:
Ballanyi et al., J. Physiology, 504(1), 127-134 (1997).*
Foote et al., Life Sciences, 42(2), 137-52 (1988).*
Bidaut-Russell et al., J. Neurochem., 57(5), 1769-73 (1991).*
Balis, G.U. and Monroe, R.R., (1964). The pharmacology of choralose,Psychopharmacology, 6:1-30.
Bennett, J.A., Abrams, J.T., Van Riper, D.F. and Horrow, J.C. (1997). Difficult or impossible ventilation after sufenanil-induced anesthesia is caused primarily by vocal cord disclosure,Anesthsiol., 87:1070-1074.
Bianchi et al., (1995). Central control of breathing in mammals: Neuronal circuitry, membrane properties, and neurotransmitters,Physiol. Rev. 75:1-45.
Cohen, M, (1979) Neurogenesis of respiratory rhythm,Physiol. Rev., 59:1105-1172.
Denavit-Saubie', M., Champagnat, J. and Zieglgansberger, W. (1978). Effects of opiates and methionine-enkephalin on pontine and bulbar respiratory neurones of the cat.,Brain Research, 155:55-67.
Duffin, J., Tian, G.-F., and Peever, J.H. (2000). Functional synaptic connections among respiratory neurons,Respiration Physiol., 122:237-246.
Ezure, K., (1990). Synaptic connections between medullary respiratory neurons and considerations on the genesiss of respiratory rhythm,Progress in Neurobiology, 35:429-450.
Fone, K.F.C. and Wilson, H., (1986). The effects of alfentanil and selected marcotic nalgesics on the rate of action potential discharge of medullary respiratory neurones in anaesthetized rats,Br. J. Pharmacol., 89:67-76.
Howard and Sears, (1990), the Effects of Opiates on the Respiratory Activity of Thoracic Motoneurons in the Anaesthesized and Decerebrate Rabbit,Journal of Physiology, 437:181-199.
Jaffe, J.H. and Martin, W.R., (1980). Opioid analgesics and antagonists:In: Goodman and Gilman's The Pharmacological Basis of Therapeutics, Sixth Edition, pp. 494-534. A.G. Gilman, L.S. Goodman, A. Gilman, S.E. Mayer and K.L. Melmon (Eds.). New York, Macmillan Publishing Co., Inc.
Jaffe, J.H. and Martin, W.R., (1990). Opioid agonists and antagonists:In: Goodman and Gilman's The Pharmac
DeWitt Ross & Stevens S.C.
Leone, Esq. Joseph T.
Spivack Phyllis G.
Wisconsin Alumni Research Foundation
LandOfFree
Method of inducing opioid analgesia and anesthesia without... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of inducing opioid analgesia and anesthesia without..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of inducing opioid analgesia and anesthesia without... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3224190